Gsa Capital Partners LLP Atea Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$3.09 - $4.56 $404,193 - $596,479	-130,807 Reduced 87.28%	19,071 $77,000
Q4 2023 Feb 16, 2024	SELL	$2.8 - $3.35 $359,542 - $430,166	-128,408 Reduced 46.14%	149,878 $457,000
Q3 2023 Nov 15, 2023	BUY	$3.0 - $3.79 $246,624 - $311,568	82,208 Added 41.93%	278,286 $834,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $169,834 - $267,714	52,908 Added 36.95%	196,078 $733,000
Q1 2023 May 12, 2023	BUY	$3.0 - $4.97 $258,750 - $428,662	86,250 Added 151.53%	143,170 $479,000
Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.17 $247,601 - $351,196	56,920 New	56,920 $274,000
Q2 2022 Aug 09, 2022	BUY	$5.33 - $8.18 $133,676 - $205,154	25,080 New	25,080 $178,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.